Myeloid Leukemia, Chronic, Chronic Phase
Conditions
Keywords
Chronic Phase Chronic Myeloid Leukemia, Molecular Response, CML, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasms by Histologic Type, Neoplasms, Myeloproliferative Disorders, Bone Marrow Diseases, Hematologic Diseases, CP-CML
Brief summary
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.
Detailed description
The drug being tested in this study is ponatinib. This study will characterize the safety and efficacy of ponatinib over a range of 3 starting doses. The study will enroll 276 participants in 3 cohorts and each cohort will have 92 participants. All the participants will be randomized to receive once-daily oral administration of 1 of 3 starting doses of ponatinib: * Cohort A: 45 mg ponatinib tablet * Cohort B: 30 mg ponatinib tablet * Cohort C: 15 mg ponatinib tablet The study is designed to consist of 2 periods: 24-cycle Main treatment period and optional treatment continuation period. Participants will be treated with their randomized dose of study drug in the Main Treatment Period until the occurrence of at least one of the following: absence of CHR by 3 months, absence of MCyR at 12 months, absence of \<=1% BCR-ABL1IS at 12 months, loss of \<=1% BCR-ABL1IS development of intolerance, or completion of all 24 cycles of treatment (whichever occurs first). Following completion of approximately 5 years or following early withdrawal, participants may enter into an optional treatment continuation period. This multi-center trial will be conducted in the United States, United Kingdom, Republic of Korea, Spain, France, Taiwan, Australia, Canada, Italy, Chile, Japan, Germany, Argentina, Poland, Czech Republic, Denmark, Hong Kong, Portugal, Russia, Singapore, Switzerland, and Sweden. The overall time to participate in this study is approximately 96 months. Participants will make a final visit to the clinic approximately 30 days after the last dose of study treatment.
Interventions
DRUGPonatinib
Tablet, taken orally once daily.
Sponsors
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Have chronic phase-chronic myelogenous leukemia/chronic myeloid leukemia (CP-CML) and have received at least two prior tyrosine kinase inhibitor (TKI) therapies and have demonstrated resistance to treatment OR have documented history of presence of T315I mutation after receiving any number of prior TKI. o\] The diagnosis of chronic myeloid leukemia (CML) will be made using standard hematopathologic and cytogenetic criteria; CP-CML will be defined by all of the following: i \<15% blasts in bone marrow ii \<30% blasts plus promyelocytes in bone marrow iii \<20% basophils in peripheral blood. iv \>= 100\*10\^9/liter (L) platelets (\>=100,000/mm\^3). v No evidence of extramedullary disease except hepatosplenomegaly vi No prior diagnosis of AP-CML, and BP-CML o\] Cytogenetic assessment at screening must demonstrate the BCR-ABL1 fusion by presence of the t(9;22) Philadelphia chromosome. i Variant translocations are only allowed provided they meet inclusion criterion 1d. o\] Resistance to prior TKI therapy is defined as follows (participants must meet at least 1 criterion): i Three months after the initiation of prior TKI therapy: No cytogenetic response (\>95% Ph+) or failure to achieve CHR or new mutation ii Six months after the initiation of prior TKI therapy: BCR-ABL1IS \>10% and/or Ph+ \>65% or new mutation iii Twelve months after the initiation of prior TKI therapy: BCR ABL1IS \>10% and/or Ph+ \>35% or new mutation iv At any time after the initiation of prior TKI therapy, the development of a new BCR-ABL1 kinase domain mutation(s) v At any time after the initiation of prior TKI therapy, the development of new clonal evolution vi At any time after the initiation of prior TKI therapy, the loss of CHR, or CCyR, or the confirmed loss of MMR in 2 consecutive tests, one of which has a BCR-ABL1IS transcript level of \>=1% or new mutation o\] \>1% of BCR-ABL1IS as shown by real-time polymerase chain reaction 2. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. 3. Have adequate renal function as defined by the following criterion: o\] Serum creatinine \<=1.5\*ULN for institution o\] Estimated creatinine clearance \>=30 milliliter per minute (mL/min) (Cockcroft-Gault formula) 4. Have adequate hepatic function as defined by the following criteria: o\] Total serum bilirubin \<=1.5\*ULN, unless due to Gilbert's syndrome o\] Alanine transaminase (ALT) \<=2.5\*ULN, or \<=5\*ULN if leukemic infiltration of the liver is present o\] Aspartate transaminase (AST) \<=2.5\*ULN, or \<=5\*ULN if leukemic infiltration of the liver is present 5. Have normal pancreatic status as defined by the following criterion: o\] Serum lipase and amylase \<=1.5\*ULN 6. Have normal QT interval corrected (Frederica) (QTcF) interval on screening electrocardiogram (ECG) evaluation, defined as QTcF of \<=450 milliseconds (ms) in males or \<=470 ms in females. 7. Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential). 8. Agree to use a highly effective form of contraception with sexual partners from randomization through at least 4 months after the end of treatment (for female and male participants who are fertile). 9. Provide written informed consent. 10. Be willing and able to comply with scheduled visits and study procedures. 11. Have recovered from toxicities related to prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 grade \<=1.
Exclusion criteria
1. Have used any approved TKIs or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is longer, prior to receiving study drug. 2. Received interferon, cytarabine, or immunotherapy within 14 days, or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of ponatinib, or have not recovered (\>grade 1 by NCI CTCAE, version 4.0) from AEs (except alopecia), due to agents previously administered. 3. Have undergone autologous or allogeneic stem cell transplant \<60 days prior to receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host disease (GVHD) or GVHD requiring immunosuppressive therapy. 4. Are being considered for hematopoietic stem cell transplant (HSCT) within 6-12 months of enrollment (note: ponatinib is not to be used as a bridge to HSCT in this trial). 5. Are taking medications with a known risk of Torsades de Pointes. 6. Have previously been treated with ponatinib. 7. Have active CNS disease as evidenced by cytology or pathology; in the absence of clinical CNS disease, lumbar puncture is not required. History itself of CNS involvement is not exclusionary if CNS has been cleared with a documented negative lumbar puncture. 8. Have clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to: o\] Any history of myocardial infarction (MI), unstable angina, cerebrovascular accident, or Transient Ischemic Attack (TIA) o\] Any history of peripheral vascular infarction, including visceral infarction o\] Any revascularization procedure, including the placement of a stent o\] Congestive heart failure (CHF) (New York Heart Association \[NYHA\] class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment o\] History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia o\] Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment 9. Have uncontrolled hypertension (that is, \>150 and \>90 for systolic blood pressure (SBP) and diastolic blood pressure (DBP) respectively). Participants with hypertension should be under treatment at study entry to ensure blood pressure control. Those requiring 3 or more antihypertensive medications should be discussed with the medical monitor. 10. Have poorly controlled diabetes defined as HbA1c values of \>7.5%. Participants with preexisting, well-controlled diabetes are not excluded. 11. Have a significant bleeding disorder unrelated to CML. 12. Have a history of alcohol abuse. 13. Have a history of either acute pancreatitis within 1 year of study enrollment or of chronic pancreatitis. 14. Have malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drug. 15. Have a history of another malignancy, other than cervical cancer in situ or basal cell or squamous cell carcinoma of the skin; the exception is if participants have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy. 16. Are pregnant or lactating. 17. Have undergone major surgery (with the exception of minor surgical procedures, such as catheter placement or BM biopsy) within 14 days prior to first dose of ponatinib. 18. Have an active infection which requires intravenous antibiotics. 19. Have a known history of human immunodeficiency virus infection; testing is not required in the absence of prior documentation or known history. 20. Have any condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with the evaluation of the drug. 21. Have hypersensitivity to the ponatinib active substance or to any of its inactive ingredients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12 | 12 months after the first dose of study treatment | MR2 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL \<=1% Breakpoint Cluster Region-Abelson Transcript Level as measured by the International Scale (BCR-ABL1IS), equivalent to a 2-log reduction in transcript. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Major Molecular Response (MMR/MR3) | 12, 24 and 60 months after the first dose of study treatment | MMR/MR3 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript). |
| Percentage of Participants With Major Cytogenetic Response (MCyR) | 12 months after the first dose of study treatment | MCyR was defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: \>0 to 35% Ph + metaphases. |
| Duration of Major Molecular Response (MMR/MR3) | Baseline up to approximately 8.9 years | Duration of MMR/MR3 was defined as the interval between the first assessment at which the criteria for \<=0.1% MMR were met until the earliest date at which loss of \<=0.1% MMR occurred, or the criteria for progression were met. Progression to accelerated phase (AP) was defined as: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast phase (BP) was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. |
| Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | From first dose up to 30 days after last dose of the study drug (up to approximately 9.8 years) | Percentage of participants with adjusted incidence rates who developed AOEs and VTEs were categorized according to arterial occlusive events and venous thrombotic events. AE is any untoward medical occurrence in participant administered medicinal investigational drug. Untoward medical occurrence does not necessarily have to have causal relationship with treatment. SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect/is medically important event that may not be immediately life-threatening/result in death or hospitalization, but may jeopardize participant/may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent. |
| Percentage of Participants With Complete Cytogenetic Response (CCyR) | Month 12 | Cytogenetic response was defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR was defined as 0% Ph+ metaphases. |
| Percentage of Participants With Molecular Response 4 (MR4) and Molecular Response 4.5 (MR4.5) | Up to approximately 9.5 years | MR4 was defined as \<=0.01% BCR-ABL1IS. MR 4.5was defined as \<=0.0032% BCR-ALB1IS. MR4 and MR4.5 by each time point means the best outcome up to each time point after randomization. |
| Percentage of Participants With Molecular Response 1 (MR1) | 3 months after the first dose of study treatment | MR1 was defined as percentage of participants achieving a ratio of \<=10% Breakpoint Cluster Region-Abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript. |
| Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | Up to approximately 9.8 years | An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. |
| Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24 | 12 and 24 months after the first dose of study treatment | DOR (≤1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for ≤1% BCR-ABL1IS are met until earliest date at which loss of ≤1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of ≤1% BCR-ABL1IS is an increase to \>1% of BCR-ABL1IS. Progression to AP: ≥15% and \<30% blasts in peripheral blood or bone marrow or ≥20% basophils in peripheral blood or bone marrow or ≥30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: ≥30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months. |
| Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3) | 12 and 24 months after the first dose of study treatment | Duration of MMR/MR3 is defined as interval between first assessment at which criteria for MMR are met until earliest date at which loss of MMR occurs, or criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at last date at which criteria for MMR are met. Loss of MMR is an increase to \>0.1% of BCR-ABL1IS. Progression to AP: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts+promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months. |
| Duration of Response in MR2 Responders | Baseline up to approximately 8.9 years | Duration of response in "responders" was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. Responders were defined as those participants who met all of the following: were randomized and treated, responded at 12 months after the initiation of study treatment, and underwent baseline polymerase chain reaction (PCR) assessment. |
| Time to Response (MR2) | Baseline up to approximately 5 years | Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. Response was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters. |
| Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML | From first dose date of study treatment up to approximately 8.9 years | Progression to AP is defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. |
| Progression-free Survival (PFS) | Up to approximately 8.9 years | PFS was defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression were met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP was defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. |
| Percentage of Participants With Complete Hematologic Response (CHR) | 3 months after the first dose of study treatment | CHR was defined as achieving all of the following measurements: white blood cells (WBC) \<= institutional upper limit of normal (ULN), platelets less than (\<)450,000 per cubic millimeter (/mm\^3), no blasts or promyelocytes in peripheral blood, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly). |
| Overall Survival (OS) | Up to approximately 8.9 years | OS was defined as the interval between the first dose of study treatment and death due to any cause, censored at the last contact date when the participant was alive. |
Countries
Argentina, Australia, Canada, Chile, Czechia, Denmark, France, Germany, Hong Kong, Italy, Poland, Portugal, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Contacts
STUDY_DIRECTORMedical Director
Takeda
Participant flow
Recruitment details
Participants took part in the study at 61 investigative sites globally from 13 July 2015 to 23 April 2025.
Pre-assignment details
Participants with chronic phase-chronic myelogenous leukemia(CP-CML) who received at least 2 prior tyrosine kinase inhibitor(TKI) therapies were enrolled in 1:1:1 ratio in 3 cohorts:ponatinib:45 milligrams(mg)(Cohort A);30mg(Cohort B);or 15mg(Cohort C). Participants who started at 45/30mg received mandatory dose reduction of their daily dose to 15mg upon achievement of less than equal to (≤)1% breakpoint cluster region-Abelson 1 transcript level as measured by International Scale (BCR-ABL1IS).
Participants by arm
| Arm | Count |
|---|---|
| Cohort A: Ponatinib 45 mg Ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily. | 94 |
| Cohort B: Ponatinib 30 mg Ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily. | 94 |
| Cohort C: Ponatinib 15 mg Participants received ponatinib 15 mg orally once daily up to data cut-off: 31 May 2020 in each 28 day Cycle. | 94 |
| Total | 282 |
Baseline characteristics
| Characteristic | Total | Cohort B: Ponatinib 30 mg | Cohort C: Ponatinib 15 mg | Cohort A: Ponatinib 45 mg |
|---|---|---|---|---|
| Age, Continuous | 48.3 years STANDARD_DEVIATION 13.45 | 48.5 years STANDARD_DEVIATION 12.9 | 48.8 years STANDARD_DEVIATION 12.71 | 47.7 years STANDARD_DEVIATION 14.77 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score Score= 0 | 219 Participants | 73 Participants | 72 Participants | 74 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score Score= 1 | 61 Participants | 20 Participants | 22 Participants | 19 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score Score= 2 | 2 Participants | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 68 Participants | 26 Participants | 20 Participants | 22 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 209 Participants | 67 Participants | 72 Participants | 70 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 5 Participants | 1 Participants | 2 Participants | 2 Participants |
| Height | 1.68 meter STANDARD_DEVIATION 0.097 | 1.68 meter STANDARD_DEVIATION 0.098 | 1.68 meter STANDARD_DEVIATION 0.09 | 1.68 meter STANDARD_DEVIATION 0.104 |
| Mutations at Baseline 1 or more mutations detected | 115 Participants | 35 Participants | 39 Participants | 41 Participants |
| Mutations at Baseline No mutation detected | 163 Participants | 58 Participants | 54 Participants | 51 Participants |
| Number of Prior Approved TKIs 1 | 6 Participants | 1 Participants | 4 Participants | 1 Participants |
| Number of Prior Approved TKIs 2 | 122 Participants | 37 Participants | 42 Participants | 43 Participants |
| Number of Prior Approved TKIs 3 | 124 Participants | 47 Participants | 35 Participants | 42 Participants |
| Number of Prior Approved TKIs 4 | 30 Participants | 9 Participants | 13 Participants | 8 Participants |
| Prior Tyrosine Kinase Inhibitor (TKIs) Bosutinib | 54 Participants | 19 Participants | 17 Participants | 18 Participants |
| Prior Tyrosine Kinase Inhibitor (TKIs) Dasatinib | 212 Participants | 76 Participants | 68 Participants | 68 Participants |
| Prior Tyrosine Kinase Inhibitor (TKIs) Imatinib | 255 Participants | 84 Participants | 86 Participants | 85 Participants |
| Prior Tyrosine Kinase Inhibitor (TKIs) Nilotinib | 219 Participants | 72 Participants | 73 Participants | 74 Participants |
| Prior Tyrosine Kinase Inhibitor (TKIs) Radotinib | 2 Participants | 1 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Race Asian | 43 Participants | 12 Participants | 15 Participants | 16 Participants |
| Race/Ethnicity, Customized Race Black or African American | 6 Participants | 2 Participants | 3 Participants | 1 Participants |
| Race/Ethnicity, Customized Race Missing | 4 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Race Other | 3 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Race Unknown | 4 Participants | 1 Participants | 3 Participants | 0 Participants |
| Race/Ethnicity, Customized Race White | 222 Participants | 77 Participants | 72 Participants | 73 Participants |
| Randomization Stratum <60/No | 155 Participants | 52 Participants | 52 Participants | 51 Participants |
| Randomization Stratum >=60/No | 21 Participants | 7 Participants | 7 Participants | 7 Participants |
| Randomization Stratum <60/Yes | 57 Participants | 19 Participants | 19 Participants | 19 Participants |
| Randomization Stratum >=60/Yes | 49 Participants | 16 Participants | 16 Participants | 17 Participants |
| Region of Enrollment Argentina | 38 Participants | 16 Participants | 7 Participants | 15 Participants |
| Region of Enrollment Austria | 2 Participants | 0 Participants | 2 Participants | 0 Participants |
| Region of Enrollment Canada | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Chile | 25 Participants | 9 Participants | 9 Participants | 7 Participants |
| Region of Enrollment Denmark | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Region of Enrollment France | 5 Participants | 1 Participants | 2 Participants | 2 Participants |
| Region of Enrollment Hong Kong | 6 Participants | 3 Participants | 2 Participants | 1 Participants |
| Region of Enrollment Italy | 3 Participants | 3 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Japan | 11 Participants | 2 Participants | 4 Participants | 5 Participants |
| Region of Enrollment Korea, Republic Of | 5 Participants | 3 Participants | 2 Participants | 0 Participants |
| Region of Enrollment Poland | 15 Participants | 6 Participants | 5 Participants | 4 Participants |
| Region of Enrollment Portugal | 2 Participants | 1 Participants | 1 Participants | 0 Participants |
| Region of Enrollment Russia | 107 Participants | 31 Participants | 38 Participants | 38 Participants |
| Region of Enrollment Singapore | 9 Participants | 3 Participants | 2 Participants | 4 Participants |
| Region of Enrollment Spain | 5 Participants | 0 Participants | 2 Participants | 3 Participants |
| Region of Enrollment Sweden | 3 Participants | 2 Participants | 1 Participants | 0 Participants |
| Region of Enrollment Taiwan, Province Of China | 7 Participants | 1 Participants | 2 Participants | 4 Participants |
| Region of Enrollment United Kingdom | 12 Participants | 4 Participants | 7 Participants | 1 Participants |
| Region of Enrollment United States | 25 Participants | 8 Participants | 7 Participants | 10 Participants |
| Sex: Female, Male Female | 141 Participants | 56 Participants | 41 Participants | 44 Participants |
| Sex: Female, Male Male | 141 Participants | 38 Participants | 53 Participants | 50 Participants |
| Time Since Diagnosis | 7.4 years STANDARD_DEVIATION 5.7 | 7.6 years STANDARD_DEVIATION 6.32 | 7.1 years STANDARD_DEVIATION 5.36 | 7.4 years STANDARD_DEVIATION 5.41 |
| Weight | 77.47 kg STANDARD_DEVIATION 18.879 | 77.56 kg STANDARD_DEVIATION 18.375 | 76.71 kg STANDARD_DEVIATION 17.434 | 78.14 kg STANDARD_DEVIATION 20.841 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 19 / 94 | 16 / 95 | 14 / 94 | 0 / 27 | 0 / 17 | 0 / 17 |
| other Total, other adverse events | 93 / 94 | 90 / 94 | 90 / 94 | 19 / 27 | 16 / 17 | 13 / 17 |
| serious Total, serious adverse events | 38 / 94 | 33 / 94 | 39 / 94 | 1 / 27 | 3 / 17 | 0 / 17 |
Outcome results
Primary
Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12
MR2 is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL \<=1% Breakpoint Cluster Region-Abelson Transcript Level as Measured by the International Scale (BCR-ABL1IS), equivalent to a 2-log reduction in transcript.
Time frame: 12 months after the first dose of study treatment
Population: ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (ie, participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12 | 44.1 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12 | 29.0 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12 | 23.1 percentage of participants |
Secondary
Duration of Major Molecular Response (MMR/MR3)
Duration of MMR/MR3 is defined as the interval between the first assessment at which the criteria for \<=0.1% MMR are met until the earliest date at which loss of \<=0.1% MMR occurs, or the criteria for progression are met. Progression to accelerated phase (AP) is defined as: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast Phase (BP) is defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Time frame: Baseline up to approximately 8 years
Secondary
Duration of Response in Responders
Duration of response in responders is defined as any participants who achieved ≤1% BCR-ABL1IS at any time during the study. Responders are defined as those participants who meet all of the following: are randomized and treated, respond at 12 months after the initiation of study treatment, and undergo baseline polymerase chain reaction (PCR) assessment.
Time frame: Baseline up to data cut-off: 31 May 2020 (Approximately 5 years)
Population: ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (ie, participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug. Data is reported for responders.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Duration of Response in Responders | NA months |
| Cohort B: Ponatinib 30 mg | Duration of Response in Responders | NA months |
| Cohort C: Ponatinib 15 mg | Duration of Response in Responders | NA months |
Secondary
Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24
DOR (≤1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for ≤1% BCR-ABL1IS are met until earliest date at which loss of ≤1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of ≤1% BCR-ABL1IS is an increase to \>1% of BCR-ABL1IS. Progression to AP: ≥15% and \<30% blasts in peripheral blood or bone marrow or ≥20% basophils in peripheral blood or bone marrow or ≥30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: ≥30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.
Time frame: 12 and 24 months after the first dose of study treatment
Population: ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (ie, participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug. Data is reported for responders.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort A: Ponatinib 45 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24 | Month 12 | 79.13 percentage of participants |
| Cohort A: Ponatinib 45 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24 | Month 24 | 73.17 percentage of participants |
| Cohort B: Ponatinib 30 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24 | Month 12 | 79.20 percentage of participants |
| Cohort B: Ponatinib 30 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24 | Month 24 | 75.60 percentage of participants |
| Cohort C: Ponatinib 15 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24 | Month 12 | 90.10 percentage of participants |
| Cohort C: Ponatinib 15 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24 | Month 24 | 90.10 percentage of participants |
Secondary
Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3)
Duration of MMR/MR3 is defined as interval between first assessment at which criteria for MMR are met until earliest date at which loss of MMR occurs, or criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at last date at which criteria for MMR are met. Loss of MMR is an increase to \>0.1% of BCR-ABL1IS. Progression to AP: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts+promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.
Time frame: 12 and 24 months after the first dose of study treatment
Population: ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (ie, participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug. Data is reported for responders.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort A: Ponatinib 45 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3) | Month 12 | 88.97 percentage of participants |
| Cohort A: Ponatinib 45 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3) | Month 24 | 88.97 percentage of participants |
| Cohort B: Ponatinib 30 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3) | Month 12 | 93.33 percentage of participants |
| Cohort B: Ponatinib 30 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3) | Month 24 | 84.00 percentage of participants |
| Cohort C: Ponatinib 15 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3) | Month 12 | 94.74 percentage of participants |
| Cohort C: Ponatinib 15 mg | Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3) | Month 24 | 94.74 percentage of participants |
Secondary
Overall Survival (OS)
OS is defined as the interval between the first does of study treatment and death due to any cause, censored at the last contact date when the participant was alive.
Time frame: Up to data cut-off: 31 May 2020 (Up to approximately 5 years)
Population: All randomized participants were included in the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Overall Survival (OS) | NA months |
| Cohort B: Ponatinib 30 mg | Overall Survival (OS) | NA months |
| Cohort C: Ponatinib 15 mg | Overall Survival (OS) | NA months |
Secondary
Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)
Percentage of participants with adjusted incidence rates who developed AOEs and VTEs were categorized according to arterial occlusive events and venous thrombotic events. AE is any untoward medical occurrence in participant administered medicinal investigational drug. Untoward medical occurrence does not necessarily have to have causal relationship with treatment. SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect/is medically important event that may not be immediately life-threatening/result in death or hospitalization, but may jeopardize participant/may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.
Time frame: From first dose up to 30 days after last dose of the study drug up to data cut-off date: 31 May 2020 (Up to approximately 5 years)
Population: Safety Population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | AOEs | 9.6 percentage of participants |
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | VTEs | 1.1 percentage of participants |
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | AEs | 100.0 percentage of participants |
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | SAEs | 34.0 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | SAEs | 25.5 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | AOEs | 5.3 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | AEs | 93.6 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | VTEs | 0 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | SAEs | 33.0 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | VTEs | 0 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | AEs | 94.7 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs) | AOEs | 3.2 percentage of participants |
Secondary
Percentage of Participants With Complete Cytogenetic Response (CCyR)
Cytogenetic response is defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR is defined as 0% Ph+ metaphases.
Time frame: Month 12
Population: ITT Cytogenetic Population included all participants who were randomized and had a cytogenetic assessment at Baseline with ≥20 metaphases examined, regardless of whether they received the assigned study drug. Overall number analyzed are participants with data available for analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Complete Cytogenetic Response (CCyR) | 34.1 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Complete Cytogenetic Response (CCyR) | 17.8 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Complete Cytogenetic Response (CCyR) | 29.2 percentage of participants |
Secondary
Percentage of Participants With Complete Hematologic Response (CHR)
CHR is defined as achieving all of the following measurements: white blood cells (WBC) \<= institutional upper limit of normal (ULN), platelets \<450,000 per cubic millimeter (/mm\^3), no blasts or promyelocytes in peripheral blood, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).
Time frame: 3 months after the first dose of study treatment
Population: All randomized participants were included in the analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Complete Hematologic Response (CHR) | 87.2 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Complete Hematologic Response (CHR) | 81.1 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Complete Hematologic Response (CHR) | 81.9 percentage of participants |
Secondary
Percentage of Participants With Major Cytogenetic Response (MCyR)
MCyR is defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: \>0 to 35% Ph + metaphases.
Time frame: 12 months after the first dose of study treatment
Population: ITT Cytogenetic Population included all participants who were randomized and had a cytogenetic assessment at Baseline with ≥20 metaphases examined, regardless of whether they received the assigned study drug. Overall number analyzed are participants with data available for analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Major Cytogenetic Response (MCyR) | 48.4 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Major Cytogenetic Response (MCyR) | 27.8 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Major Cytogenetic Response (MCyR) | 43.8 percentage of participants |
Secondary
Percentage of Participants With Major Molecular Response (MMR/MR3)
MMR/MR3 is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript).
Time frame: 12 months after the first dose of study treatment
Population: ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (ie, participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Major Molecular Response (MMR/MR3) | 17.2 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Major Molecular Response (MMR/MR3) | 20.4 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Major Molecular Response (MMR/MR3) | 16.5 percentage of participants |
Secondary
Percentage of Participants With Molecular Response 1 (MR1)
MR1 is defined as percentage of participants achieving a ratio of \<=10% Breakpoint Cluster Region-abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript.
Time frame: 3 months after the first dose of study treatment
Population: ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (ie, participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Molecular Response 1 (MR1) | 52.7 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Molecular Response 1 (MR1) | 44.1 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Molecular Response 1 (MR1) | 42.9 percentage of participants |
Secondary
Percentage of Participants With Molecular Response 4 (MR4) and Molecular Response (MR4.5)
MR4 is defined as \<=0.01% BCR-ABL1IS. MR 4.5 is defined as \<=0.0032% BCR-ALB1IS.
Time frame: Up to approximately 8 years
Secondary
Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML
Progression to AP is defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Time frame: From first dose date of study treatment up to data cut-off: 31 May 2020 (Approximately 5 years)
Population: All randomized participants were included in the analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML | Progressed to AP-CML | 10.6 percentage of participants |
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML | Progressed to BP-CML | 3.2 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML | Progressed to BP-CML | 1.1 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML | Progressed to AP-CML | 9.5 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML | Progressed to AP-CML | 11.7 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML | Progressed to BP-CML | 1.1 percentage of participants |
Secondary
Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: Up to data cut-off: 31 May 2020 (Approximately 5 years)
Population: Safety Population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Dose Reduction | 45.7 percentage of participants |
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Treatment Discontinuation | 19.1 percentage of participants |
| Cohort A: Ponatinib 45 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Dose Interruption | 71.3 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Dose Reduction | 35.1 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Treatment Discontinuation | 16.0 percentage of participants |
| Cohort B: Ponatinib 30 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Dose Interruption | 61.7 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Treatment Discontinuation | 13.8 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Dose Interruption | 58.5 percentage of participants |
| Cohort C: Ponatinib 15 mg | Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption | TEAEs Leading to Dose Reduction | 31.9 percentage of participants |
Secondary
Progression-free Survival (PFS)
PFS is defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression are met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP is defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Time frame: Up to data cut-off: 31 May 2020 (Up to approximately 5 years)
Population: All randomized participants were included in the analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Progression-free Survival (PFS) | NA months |
| Cohort B: Ponatinib 30 mg | Progression-free Survival (PFS) | NA months |
| Cohort C: Ponatinib 15 mg | Progression-free Survival (PFS) | 45.64 months |
Secondary
Time to Response
Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.
Time frame: Baseline up to data cut-off: 31 May 2020 (Approximately 5 years)
Population: ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (ie, participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug. Data is reported for the responders.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort A: Ponatinib 45 mg | Time to Response | 6.00 months |
| Cohort B: Ponatinib 30 mg | Time to Response | 3.04 months |
| Cohort C: Ponatinib 15 mg | Time to Response | 6.04 months |